Cerdulatinib
As of the edition of 20 October 2026, Cerdulatinib is a small molecule: stopped in 2023; acts on JAK3 and TYK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Organon | Lead sponsor of trials | 2019 to now |
| Portola Pharmaceuticals | Lead sponsor of trials | 2019 to now |
| AstraZeneca | Lead sponsor of trials |